The is no question in my mind that the Dec 7th Upd
Post# of 148261
But what really struck me in the PR was Dr Stefan Glück who has been a Principal Investigator for over 37 breast cancer clinical studies. He has also served in roles for Regeneron and Celgene, focusing on immuno-oncology in solid tumors and acquiring early assets.
I repeat: Regeneron and Celgene, focusing on immuno-oncology in solid tumors and acquiring early assets. Acquiring early assets! Hello!